Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eupraxia Pharmaceuticals Inc (EPRX)

Eupraxia Pharmaceuticals Inc (EPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 294,161
  • Shares Outstanding, K 35,961
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,500 K
  • EBIT $ -30 M
  • EBITDA $ -30 M
  • 60-Month Beta 1.20
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.18

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.16
  • Number of Estimates 4
  • High Estimate -0.11
  • Low Estimate -0.23
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +23.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.30 +12.05%
on 02/19/26
9.16 -10.75%
on 02/03/26
-0.81 (-9.01%)
since 01/27/26
3-Month
5.72 +43.01%
on 12/02/25
9.32 -12.23%
on 01/21/26
+1.95 (+31.30%)
since 11/26/25
52-Week
2.68 +205.21%
on 04/07/25
9.32 -12.23%
on 01/21/26
+3.94 (+93.05%)
since 02/27/25

Most Recent Stories

More News
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option

VICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging...

EPRX : 8.18 (unch)
EPRX.TO : 11.14 (-0.80%)
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants

VICTORIA, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging...

EPRX : 8.18 (unch)
EPRX.TO : 11.14 (-0.80%)
Eupraxia Pharmaceuticals Announces Proposed Public Offering

VICTORIA, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging...

EPRX : 8.18 (unch)
EPRX.TO : 11.14 (-0.80%)
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy 

At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete improvement in tissue health 1 . At lower doses, patients maintained the improvements...

EPRX : 8.18 (unch)
EPRX.TO : 11.14 (-0.80%)
Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI

The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability data previously reported from Cohort 5; Cohorts 5 & 6 are the only groups to reach 52 weeks thus far....

EPRX : 8.18 (unch)
EPRX.TO : 11.14 (-0.80%)
Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by...

EPRX : 8.18 (unch)
EPRX.TO : 11.14 (-0.80%)
Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs

Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dose planned in this trial. Patients...

EPRX : 8.18 (unch)
EPRX.TO : 11.14 (-0.80%)
Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option

VICTORIA, British Columbia, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging...

EPRX : 8.18 (unch)
EPRX.TO : 11.14 (-0.80%)
Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares

VICTORIA, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging...

EPRX : 8.18 (unch)
EPRX.TO : 11.14 (-0.80%)
Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares

VICTORIA, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging...

EPRX : 8.18 (unch)
EPRX.TO : 11.14 (-0.80%)

Business Summary

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment...

See More

Key Turning Points

3rd Resistance Point 8.37
2nd Resistance Point 8.29
1st Resistance Point 8.23
Last Price 8.18
1st Support Level 8.09
2nd Support Level 8.01
3rd Support Level 7.95

See More

52-Week High 9.32
Last Price 8.18
Fibonacci 61.8% 6.78
Fibonacci 50% 6.00
Fibonacci 38.2% 5.22
52-Week Low 2.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar